Intelligent Bio Solutions Beheer

Beheer criteriumcontroles 1/4

De CEO Intelligent Bio Solutions is Harry Simeonidis, benoemd in Oct2022, heeft een ambtstermijn van 2.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 446.62K, bestaande uit 65.7% salaris en 34.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.92% van de aandelen van het bedrijf, ter waarde $ 62.88K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0 jaar en 2.1 jaar.

Belangrijke informatie

Harry Simeonidis

Algemeen directeur

US$446.6k

Totale compensatie

Percentage CEO-salaris	65.7%
Dienstverband CEO	2.1yrs
Eigendom CEO	0.9%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Harry Simeonidis's beloning veranderd ten opzichte van Intelligent Bio Solutions's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$10m
Jun 30 2024	US$447k	US$293k	-US$10m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	n/a	n/a	-US$13m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	US$343k	US$276k	-US$11m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	n/a	n/a	-US$5m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	US$355k	US$250k	-US$8m
Mar 31 2022	n/a	n/a	-US$7m
Dec 31 2021	n/a	n/a	-US$9m
Sep 30 2021	n/a	n/a	-US$7m
Jun 30 2021	US$351k	US$240k	-US$7m
Mar 31 2021	n/a	n/a	-US$7m
Dec 31 2020	n/a	n/a	-US$4m
Sep 30 2020	n/a	n/a	-US$3m
Jun 30 2020	US$207k	US$157k	-US$3m

Compensatie versus markt: De totale vergoeding ($USD 446.62K ) Harry } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.07K ).

Compensatie versus inkomsten: De vergoeding van Harry is gestegen terwijl het bedrijf verliesgevend is.

CEO

Harry Simeonidis (56 yo)

2.1yrs

Tenure

US$446,622

Compensatie

Mr. Harry Simeonidis serves as Chief Executive Officer of Intelligent Bio Solutions Inc. since October 2022 and serves as its President since October 26, 2022. He had been Non-Executive Director of FarmaFo...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jonathan Hurd	Independent Director	6.6yrs	US$35.00k	0.0014% $ 98.3
Jason Isenberg	Independent Director	2.1yrs	US$33.75k	geen gegevens
Nicola Fraser	Independent Director	less than a year	US$3.67k	geen gegevens

2.1yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van INBS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.1 jaar), wat duidt op een nieuw bestuur.

Intelligent Bio Solutions Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Intelligent Bio Solutions Inc. Announces Board Changes

Intelligent Bio Solutions Inc., Annual General Meeting, Dec 13, 2023

Intelligent Bio Solutions Inc., Annual General Meeting, Feb 08, 2023

High number of new directors

High number of new directors

Intelligent Bio Solutions Inc. Elects Harry Simeonidis as the Company’s President Effective as of October 26, 2022

Recent updates

Intelligent Bio Solutions Inc. Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission

First quarter 2025 earnings released: US$0.70 loss per share (vs US$12.49 loss in 1Q 2024)

Intelligent Bio Solutions Inc. Provides Revenue Guidance for the First Quarter Ended September 30, 2024

GPS Marine Adopts Intelligent Bio Solutions’ Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services

Intelligent Bio Solutions Concludes In-Clinic Testing for Clinical Study Plan, Advancing Toward FDA 510(K) Submission

New major risk - Revenue and earnings growth

New major risk - Share price stability

Intelligent Bio Solutions Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

Intelligent Bio Solutions Inc. Announces the Successful Completion of Biocompatibility Testing of Its Intelligent Fingerprinting Drug Screening System

Intelligent Bio Solutions Inc. Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology

Forecast to breakeven in 2026

Intelligent Bio Solutions Inc. Announces Board Changes

Intelligent Bio Solutions Inc. Completes Recruitment and Begins Subject Screening for FDA 510(K) Pharmacokinetic Study

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Intelligent Bio Solutions Inc. announced that it has received $10.116165 million in funding

Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders’ Equity Requirement

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Intelligent Bio Solutions Inc. Provides Unaudited Preliminary Earnings Guidance for the Second Quarter and Six Months Ended December 31, 2023

Intelligent Bio Solutions Provides Nasdaq Compliance Update

Intelligent Bio Solutions Receives NATA Accreditation for Its Revolutionary Fingerprint Sweat Drug Screening System

Intelligent Bio Solutions Inc., Annual General Meeting, Dec 13, 2023

New minor risk - Profitability

New major risk - Share price stability

Intelligent Bio Solutions Inc. Debuts Intelligent Fingerprinting Drug Screening Solution At the 2023 Workplace Health & Safety Show in Sydney, Australia

Intelligent Bio Solutions Inc. Completes Critical Development Milestone in Plans to Add Ketamine and Tramadol to Fingerprint Drug Test

Consensus EPS estimates fall by 32%

Price target decreased by 18% to US$11.30

Forecast to breakeven in 2026

Consensus revenue estimates increase by 19%, EPS downgraded

Consensus revenue estimates decrease by 21%

Consensus revenue estimates decrease by 39%

Intelligent Bio Solutions Inc. Files FDA 513(g) Regulatory Submission for Intelligent Fingerprinting Drug Screening Cartridge

Intelligent Bio Solutions Inc. Announces It Has Successfully Completed the Review of Results from Milestone 7

Intelligent Bio Solutions Inc. announced that it has received $0.220578 million in funding

Intelligent Bio Solutions Inc., Annual General Meeting, Feb 08, 2023

High number of new directors

Intelligent Bio Solutions Inc. to Report Q1, 2023 Results on Nov 09, 2022

High number of new directors

Intelligent Bio Solutions Inc. Elects Harry Simeonidis as the Company’s President Effective as of October 26, 2022

GBS Inc. Announces Board Appointments

GBS Inc. (NasdaqCM:GBS) acquired Intelligent Fingerprinting Limited.

GBS acquires Intelligent Fingerprinting in all-stock deal

GBS GAAP EPS of -$0.57, revenue of $0.44M

GBS Inc. to Report Q4, 2022 Results on Aug 31, 2022

High number of new directors

GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood

GBS Inc. (NasdaqCM:GBS) entered into a exclusive agreement to acquire Intelligent Fingerprinting Limited.

GBS Inc., Annual General Meeting, Jun 16, 2022

GBS Inc. to Report Q3, 2022 Results on May 10, 2022

GBS Inc. Announces Resignation of Leon Kempler as Member of the Board

High number of new and inexperienced directors

GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial At Sutter Health Mills-Peninsula Medical Center

Gbs Inc. Announces Resignation of Prof. Jonathan Sessler, A Member of the Board of Directors

No longer forecast to breakeven

GBS Inc. to Report Q2, 2022 Results on Feb 10, 2022

Gbs Inc. Announces Application for FDA Breakthrough Device Designation to Fast Track Rapid Saliva Glucose Test

GBS Inc. Announces Plans for Clinical SARS-CoV-2 Antibody Trials Following Validation Study

High number of new directors

GBS Inc.: Can Its Technology Come Through?

GBS Inc.: Pioneering Non-Invasive, Real-Time Diagnostic Testing

Is GBS (NASDAQ:GBS) In A Good Position To Invest In Growth?

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd